ASCO 2020-话题@MedSci

#ASCO 2020#

32篇内容 | 1987人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1344228, encodeId=8c62134422817, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020：MEK162（贝美替尼）联合伊马替尼治疗晚期胃肠道间质瘤II期临床研究, objectType=article, longId=194645, objectId=1e85194645d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e85194645d2, replyNumber=0, likeNumber=53, createdTime=2020-05-25, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e85194645d2, moduleTitle=ASCO 2020：MEK162（贝美替尼）联合伊马替尼治疗晚期胃肠道间质瘤II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e85194645d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344227, encodeId=0f27134422e95, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020：罗氏的TIGIT单抗tiragolumab与PD-L1单抗Tecentriq联合，延长了非小细胞肺癌患者生存期, objectType=article, longId=194315, objectId=4a69194315ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a69194315ed, replyNumber=0, likeNumber=67, createdTime=2020-05-19, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a69194315ed, moduleTitle=ASCO 2020：罗氏的TIGIT单抗tiragolumab与PD-L1单抗Tecentriq联合，延长了非小细胞肺癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a69194315ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344226, encodeId=8f4d13442269b, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020：PD-1单抗Keytruda在三阴性乳腺癌中脱颖而出, objectType=article, longId=194255, objectId=475f19425533, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=475f19425533, replyNumber=0, likeNumber=79, createdTime=2020-05-18, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=475f19425533, moduleTitle=ASCO 2020：PD-1单抗Keytruda在三阴性乳腺癌中脱颖而出, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=475f19425533)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344224, encodeId=ef47134422409, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020：信达生物的抗PD-L1单抗TYVYT（Sintilimab）显着改善了食管鳞状细胞癌患者的总体生存率(ORIENT-2研究), objectType=article, longId=194241, objectId=a91619424150, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a91619424150, replyNumber=0, likeNumber=72, createdTime=2020-05-17, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a91619424150, moduleTitle=ASCO 2020：信达生物的抗PD-L1单抗TYVYT（Sintilimab）显着改善了食管鳞状细胞癌患者的总体生存率(ORIENT-2研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a91619424150)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344225, encodeId=cf96134422576, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020：PD-1单抗Opdivo、CTLA-4单抗Yervoy联合化疗一线治疗非小细胞肺癌，将死亡风险降低31％, objectType=article, longId=194237, objectId=1da819423ef7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1da819423ef7, replyNumber=0, likeNumber=80, createdTime=2020-05-17, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1da819423ef7, moduleTitle=ASCO 2020：PD-1单抗Opdivo、CTLA-4单抗Yervoy联合化疗一线治疗非小细胞肺癌，将死亡风险降低31％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1da819423ef7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344223, encodeId=aeeb134422321, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020：大会摘要上线, objectType=article, longId=194233, objectId=b6b4194233ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6b4194233ff, replyNumber=0, likeNumber=83, createdTime=2020-05-17, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6b4194233ff, moduleTitle=ASCO 2020：大会摘要上线, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6b4194233ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344222, encodeId=601d1344222e0, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020：安罗替尼18项研究成果亮相大会, objectType=article, longId=193343, objectId=8b5c19334374, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b5c19334374, replyNumber=0, likeNumber=77, createdTime=2020-05-03, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b5c19334374, moduleTitle=ASCO 2020：安罗替尼18项研究成果亮相大会, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b5c19334374)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344221, encodeId=b2e41344221c8, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020：特瑞普利单抗9项研究成果亮相ASCO大会, objectType=article, longId=193341, objectId=d17819334188, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d17819334188, replyNumber=0, likeNumber=67, createdTime=2020-05-03, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d17819334188, moduleTitle=ASCO 2020：特瑞普利单抗9项研究成果亮相ASCO大会, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d17819334188)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344220, encodeId=550c13442204b, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020：11项中国研究入选口头报告，17项Poster报告, objectType=article, longId=193268, objectId=ea9f193268d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea9f193268d6, replyNumber=0, likeNumber=69, createdTime=2020-05-02, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea9f193268d6, moduleTitle=ASCO 2020：11项中国研究入选口头报告，17项Poster报告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea9f193268d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344219, encodeId=686e1344219b3, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020年度胃肠道癌专题讨论会：LONSURF和Futibatinib（TAS-120）的全新数据, objectType=article, longId=186810, objectId=ee3118681049, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ee3118681049, replyNumber=0, likeNumber=69, createdTime=2020-01-29, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee3118681049, moduleTitle=ASCO 2020年度胃肠道癌专题讨论会：LONSURF和Futibatinib（TAS-120）的全新数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee3118681049)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344218, encodeId=44ef13442189d, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020年度胃肠道癌专题讨论会：礼来的pegilodecakin未达到试验预期, objectType=article, longId=186805, objectId=c58218680512, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c58218680512, replyNumber=0, likeNumber=91, createdTime=2020-01-29, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c58218680512, moduleTitle=ASCO 2020年度胃肠道癌专题讨论会：礼来的pegilodecakin未达到试验预期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c58218680512)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1344217, encodeId=018d134421e3f, content=<a href='/topic/show?id=7649283021' target=_blank style='color:#2F92EE;'>#ASCO 2020#</a>, objectTitle=ASCO 2020年度胃肠道癌专题讨论会：SBP-101的I期临床数据, objectType=article, longId=186734, objectId=0fc9186e3483, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fc9186e3483, replyNumber=0, likeNumber=69, createdTime=2020-01-27, rootId=0, userName=ms24272190615788285182, userId=4e842500199, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fc9186e3483, moduleTitle=ASCO 2020年度胃肠道癌专题讨论会：SBP-101的I期临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fc9186e3483)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ASCO 2020

2020-05-29

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020：MEK162（贝美替尼）联合伊马替尼治疗晚期胃肠道间质瘤II期临床研究

2020-05-25

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020：罗氏的TIGIT单抗tiragolumab与PD-L1单抗Tecentriq联合，延长了非小细胞肺癌患者生存期

2020-05-19

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020：PD-1单抗Keytruda在三阴性乳腺癌中脱颖而出

2020-05-18

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020：信达生物的抗PD-L1单抗TYVYT（Sintilimab）显着改善了食管鳞状细胞癌患者的总体生存率(ORIENT-2研究)

2020-05-17

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020：PD-1单抗Opdivo、CTLA-4单抗Yervoy联合化疗一线治疗非小细胞肺癌，将死亡风险降低31％

2020-05-17

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020：大会摘要上线

2020-05-17

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020：安罗替尼18项研究成果亮相大会

2020-05-03

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020：特瑞普利单抗9项研究成果亮相ASCO大会

2020-05-03

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020：11项中国研究入选口头报告，17项Poster报告

2020-05-02

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020年度胃肠道癌专题讨论会：LONSURF和Futibatinib（TAS-120）的全新数据

2020-01-29

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020年度胃肠道癌专题讨论会：礼来的pegilodecakin未达到试验预期

2020-01-29

ms24272190615788285182 (审核中...)

前往app查看评论内容

#ASCO 2020#

ASCO 2020年度胃肠道癌专题讨论会：SBP-101的I期临床数据

2020-01-27

科室
- - 订阅+
  - 更多科室
工具
服务